This company listing is no longer active
OT10 Stock Overview
Orchard Therapeutics plc, a gene therapy company, research, develops, and commercialize hematopoietic stem cell and gene therapies in the United Kingdom, Italy, France, and Germany. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Orchard Therapeutics plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$14.60 |
| 52 Week High | US$15.60 |
| 52 Week Low | US$4.02 |
| Beta | 0.55 |
| 1 Month Change | -0.68% |
| 3 Month Change | -0.68% |
| 1 Year Change | 137.40% |
| 3 Year Change | -69.33% |
| 5 Year Change | n/a |
| Change since IPO | -88.16% |
Recent News & Updates
Recent updates
Shareholder Returns
| OT10 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.8% | 0.5% |
| 1Y | 137.4% | -12.7% | 14.4% |
Return vs Industry: OT10 exceeded the German Biotechs industry which returned -26.9% over the past year.
Return vs Market: OT10 exceeded the German Market which returned -0.9% over the past year.
Price Volatility
| OT10 volatility | |
|---|---|
| OT10 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.8% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in DE Market | 12.8% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: OT10 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine OT10's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 166 | Bobby Gaspar | www.orchard-tx.com |
Orchard Therapeutics plc, a gene therapy company, research, develops, and commercialize hematopoietic stem cell and gene therapies in the United Kingdom, Italy, France, and Germany. It offers OTL-200, an ex vivo autologous hematopoietic stem cell gene therapy for the treatment of patients with metachromatic leukodystrophy under the Libmeldy brand; and Strimvelis, a gammaretroviral vector-based gene therapy for the treatment of adenosine deaminase deficiency. The company’s program for neurodegenerative disorders comprises clinical proof of concept-stage program, which includes OTL-203 for the treatment of mucopolysaccharidosis type I and OTL-201 for mucopolysaccharidosis type IIIA, or MPS-IIIA; and pre-clinical program, OTL-204 for the treatment of frontotemporal dementia with progranulin mutations.
Orchard Therapeutics plc Fundamentals Summary
| OT10 fundamental statistics | |
|---|---|
| Market cap | €348.84m |
| Earnings (TTM) | -€66.92m |
| Revenue (TTM) | €20.04m |
17.4x
P/S Ratio-5.2x
P/E RatioIs OT10 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OT10 income statement (TTM) | |
|---|---|
| Revenue | US$21.84m |
| Cost of Revenue | US$79.52m |
| Gross Profit | -US$57.68m |
| Other Expenses | US$15.24m |
| Earnings | -US$72.92m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.20 |
| Gross Margin | -264.11% |
| Net Profit Margin | -333.90% |
| Debt/Equity Ratio | 31.9% |
How did OT10 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/01/24 16:33 |
| End of Day Share Price | 2024/01/24 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Orchard Therapeutics plc is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Charles Duncan | Cantor Fitzgerald & Co. |
| Emma Nealon | Cantor Fitzgerald & Co. |
| Graig Suvannavejh | Goldman Sachs |